IVVD Earnings

IVVD reported its earnings on 2026-03-24, showcasing a revenue of against an estimate of 16.10M, resulting in a 0% surprise. The EPS was 0, surpassing the expected -0.06 by 0%. The stock experienced a 0% price change on the earnings day and a 0% change over the next five days, reflecting market reactions to the results.

Following IVVD's earnings announcement on 2026-03-24, the stock price moved by 0% on the day of the release. Over the subsequent five days, it saw a 0% change. Historically, IVVD's stock price tends to shift by an average of -1.53% in the 10 days leading up to earnings and 6.61% in the 10 days following, providing insight into potential market.

For 2025/Q4, analysts estimate IVVD's annual revenue to reach 14.21M, while the EPS is projected at -0.09. These estimates reflect recent revisions, with revenue estimates unchanged by 0% and EPS estimates unchanged by 0% over the past three months, indicating analyst expectation in the company's performance.

The correlation between IVVD's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock's fundamentals. Over the past three months, revenue estimates for FY2025 were unchanged by 0%, while EPS estimates moved unchanged by 0%. This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, IVVD's stock price typically moves by -1.53% in the 10 days before its earnings and 6.61% in the 10 days after. For the upcoming 2025/Q4 earnings, analysts expect an EPS of -0.09 and revenue of 14.21M.

The earnings call presents a mix of positive and negative factors. Strong revenue growth and capital raised are positives, but regulatory and clinical trial uncertainties, along with competitive pressures, pose significant risks. The Q&A section reveals management's vague responses on regulatory coordination, adding to uncertainties. While the company's market strategy for VYD2311 is ambitious, the absence of concrete guidance on overcoming regulatory hurdles tempers optimism. Given these mixed signals, the stock price is likely to remain stable, resulting in a neutral rating.